siRNA order: sequences, controls and knockdown you can interpret

Designing the experiment

1. Order several independent sequences. Two or preferably three non overlapping sequences against the same target, used separately. A phenotype seen with one sequence and not the others is an off target effect, and only independent sequences can distinguish the two.
2. Include the controls that actually control something. A non targeting sequence matched for chemistry and concentration, a delivery only condition, and where possible a rescue with a resistant version of the target. The rescue is the strongest evidence available and the least often done.
3. Choose the modality by compartment and duration. Short interfering duplexes act in the cytoplasm and are transient. Antisense chemistry reaches nuclear species and can work without a delivery reagent in some settings. The target's location and the required duration decide which.
4. Solve delivery before optimising sequence. In hard to transfect and primary cells, delivery efficiency dominates outcome. Establish delivery with a labelled control and a well characterised positive sequence before concluding anything about your target.
5. Measure knockdown at the protein, and time it properly. Transcript reduction is not protein reduction, and a long lived protein can persist well past the transcript. Measure the protein, and choose the phenotype timepoint from the protein curve rather than from convention.
6. Use the lowest effective concentration. Off target effects scale with concentration. Titrate to the lowest dose that gives adequate knockdown rather than using a default, and report the concentration with the result.

Off target activity is the default, not the exception

Every silencing sequence has partial complementarity to other transcripts, and some of those interactions produce phenotypes. This is not a flaw in a particular reagent; it is a property of the technique, and the experimental design has to account for it.

The design that accounts for it is independent sequences plus a rescue. Anything less produces a result that a careful reader will discount, and rightly.

Timing is a design decision

Knockdown rises and falls over days, and the phenotype follows the protein rather than the transcript. Reading the phenotype at a fixed convenient timepoint frequently misses the window in which the protein was actually depleted.

Measure the protein over a time course once, then choose the phenotype timepoint from that curve and use it consistently. It is one extra experiment that makes every subsequent one interpretable.

The reagent is chosen per cell type, not once

Transfection efficiency and toxicity vary enormously between cell types, and the reagent that is best in a robust adherent line is frequently useless in a primary or suspension cell. The only reliable approach is a small panel tested on your own cells with a viability readout alongside.

Where cells resist chemical transfection entirely, the alternatives are electroporation, which is harsh but works on almost anything, or a viral vector delivering a hairpin. Each changes the experiment, and persisting with a reagent that kills the cells is the worst of the three options.

Delivery in an animal is a different problem

Naked duplexes are degraded and cleared quickly and do not enter most cells, so in vivo work depends on chemical modification for stability and on a delivery strategy that reaches the intended tissue. That is the whole difficulty of the field rather than a detail.

A sugar ligand conjugated to the duplex is taken up by a receptor abundant on liver cells, which is why hepatic targets dominate the approved products. Reaching other tissues remains the open problem, and a reagent that works in culture says nothing about it.

Inhibiting a microRNA is not knocking down a gene

An inhibitor is a modified oligonucleotide that sequesters a small RNA so it cannot act on its targets, which raises the expression of many transcripts at once rather than reducing one. The phenotype is therefore diffuse and needs different controls.

The control is a scrambled inhibitor of the same chemistry and length, and the evidence is a change in several validated targets rather than one. Reading such an experiment as a single-gene result is the usual over-interpretation.

galnac sirna, and how the conjugate targets the liver

A triantennary N-acetylgalactosamine conjugate binds the asialoglycoprotein receptor, which is expressed at very high density on hepatocytes and recycles quickly, so a subcutaneously injected duplex is taken into liver cells without a lipid particle. That is the delivery breakthrough behind the approved hepatic silencing drugs, and it comes with a chemistry package: a heavily stabilised backbone with two prime modifications and phosphorothioate linkages, since the duplex has to survive the journey and then persist inside the cell for months of effect.

An a375 cell line and the mutation it carries

The a375 cell line is a melanoma line carrying the common BRAF mutation, which is why it is the standard model for inhibitors of that pathway and why a resistant derivative is the usual comparison. Its identity and passage history belong in the record, and a line grown far past its original passage drifts in growth rate and drug response.

A huvec cell line and what primary means here

A huvec cell line is usually a primary culture rather than an immortalised line, so it has a limited passage span, it changes phenotype as it approaches it, and every vial is a donor. Endothelial medium with the stated supplements is what keeps the phenotype, and a marker check rather than morphology is what confirms the culture is still endothelial.

bewo cells and the trophoblast model

bewo cells are a choriocarcinoma line used as a trophoblast barrier model, and the property they are bought for, a polarised monolayer with measurable transport, appears only under stated culture conditions and takes days. Transepithelial resistance is the acceptance check before a transport experiment, and the line is not a substitute for primary trophoblast in differentiation work.

human astrocytes and what the source decides

human astrocytes are supplied as primary cultures, as immortalised lines or as stem cell derived preparations, and the three differ in reactivity, in proliferation and in how much of the mature phenotype they carry. Serum drives a reactive state, so a serum free protocol and a marker panel are what make an astrocyte result interpretable rather than the species alone.

Common questions

How many sequences are enough?

At least two independent ones, three if the phenotype is the main claim. Pools are convenient and can mask a single dominant off target effect, so where a conclusion rests on the result, individual sequences are more informative.

Is a rescue experiment always necessary?

For a claim that a phenotype is caused by loss of a specific target, it is the strongest evidence and increasingly expected. It is not always feasible, and where it is not, independent sequences and a dose response are the fallback.

Why does knockdown work in a cell line and not in primary cells?

Delivery, almost always. Primary cells are harder to transfect and more sensitive to the reagents, which is why electroporation, conjugated chemistries or viral expression are used there instead of lipid transfection.

Transcript or protein for confirming knockdown?

Protein, because that is what the phenotype depends on. Transcript measurement is a useful early check and can be misleading on its own when the protein is stable.

Which is the best siRNA transfection reagent?

There is no general answer: efficiency and toxicity vary by cell type. Test a small panel on your own cells with a viability readout, and move to electroporation or a viral hairpin if the cells resist chemical transfection.

Browse by service class

• Compare Gene synthesis on advertised prices